KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Biocryst Pharmaceuticals (BCRX) Current Deferred Revenue: 2010-2015

Historic Current Deferred Revenue for Biocryst Pharmaceuticals (BCRX) over the last 3 years, with Sep 2015 value amounting to $2.1 million.

  • Biocryst Pharmaceuticals' Current Deferred Revenue rose 41.93% to $2.1 million in Q3 2015 from the same period last year, while for Sep 2015 it was $2.1 million, marking a year-over-year increase of 41.93%. This contributed to the annual value of $5.6 million for FY2014, which is 280.52% up from last year.
  • As of Q3 2015, Biocryst Pharmaceuticals' Current Deferred Revenue stood at $2.1 million, which was down 67.43% from $6.5 million recorded in Q2 2015.
  • Biocryst Pharmaceuticals' 5-year Current Deferred Revenue high stood at $9.8 million for Q4 2011, and its period low was $1.4 million during Q4 2012.
  • For the 3-year period, Biocryst Pharmaceuticals' Current Deferred Revenue averaged around $3.0 million, with its median value being $1.5 million (2013).
  • Its Current Deferred Revenue has fluctuated over the past 5 years, first crashed by 85.78% in 2012, then surged by 335.43% in 2015.
  • Over the past 5 years, Biocryst Pharmaceuticals' Current Deferred Revenue (Quarterly) stood at $9.8 million in 2011, then crashed by 85.78% to $1.4 million in 2012, then rose by 5.82% to $1.5 million in 2013, then skyrocketed by 280.52% to $5.6 million in 2014, then spiked by 41.93% to $2.1 million in 2015.
  • Its Current Deferred Revenue was $2.1 million in Q3 2015, compared to $6.5 million in Q2 2015 and $5.5 million in Q1 2015.